Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 2Sarcoma 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Pheochromocytoma 1Paraganglioma 1Kidney Neoplasms 1Gastrointestinal Stromal Tumors 1Carcinoma, Renal Cell 1

Interventions

Filgrastim 10Ifosfamide 6Carboplatin 5Radiotherapy 4Peripheral Blood Stem Cell Transplantation 4Doxorubicin 4Cyclophosphamide 4pembrolizumab 3Thiotepa 3Temozolomide 3Etoposide 3Busulfan 3sargramostim 2ixabepilone 2fludarabine phosphate 2etoposide phosphate 2belinostat 2Radiotherapy, Intensity-Modulated 2Radiosurgery 2Paclitaxel 2Mycophenolic Acid 2Melphalan 2Granulocyte Colony-Stimulating Factor 2Gemcitabine 2Bortezomib 2Antilymphocyte Serum 2Amifostine 2tremelimumab 1seribantumab 1poly ICLC 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Kidney Neoplasms × guadecitabine × Sarcoma × Clear all
NCT03165721 2026-02-18

A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
9 enrolled 11 charts
CNSEndocrineGastrointestinalGenitourinarySarcoma

Carcinoma, Renal Cell, Kidney Neoplasms, Paraganglioma, Pheochromocytoma, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡